Jupiter Neurosciences (JUNS) Cash from Financing Activities (2023 - 2024)
Jupiter Neurosciences (JUNS) posted quarterly Cash from Financing Activities of $7.5 million for Q4 2024, up 5642.34% year-over-year from $130000.0 in Q1 2024, and up 26560.84% quarter-over-quarter from $28000.0 in Q3 2024.
Jupiter Neurosciences (JUNS) Cash from Financing Activities (2023 - 2024) Analysis & Trends
Jupiter Neurosciences (JUNS) has reported Cash from Financing Activities for 2 consecutive years, with $7.5 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Cash from Financing Activities rose 5642.34% year-over-year to $7.5 million; the TTM figure through Dec 2024 stood at $7.7 million (changed N/A YoY), while the FY2025 annual figure was $5.4 million, down 28.99% from the prior year.
- Cash from Financing Activities advanced to $7.5 million in Q4 2024 per JUNS's latest filing, from $28000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $7.5 million in Q4 2024 and bottomed at $28000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Jupiter Neurosciences | 3.37 Mn | 1.85 Mn | 21,064.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 7.47 Mn |
| Dec 31, 2024 | 7.47 Mn |
| Sep 30, 2024 | 28,000.00 |
| Sep 30, 2024 | 28,000.00 |
| Jun 30, 2024 | 114,000.00 |
| Jun 30, 2024 | 114,000.00 |
| Mar 31, 2024 | 45,000.00 |
| Mar 31, 2024 | 45,000.00 |
| Dec 31, 2023 | 130,000.00 |
| Dec 31, 2023 | 130,000.00 |